Table 5. Relapse Cohort . Any cGVHD .... | American Society of Hematology

Table 5.

Relapse

Cohort	Any cGVHD		Lim, ext		Mild, mod, sev		Low, int, high
Cohort	RR^5-150	95% CI	RR^5-150	95% CI	RR^5-150	95% CI	RR^5-150	95% CI
IBMTR-1	0.5^5-152	(0.3-0.7)	0.5	(0.3-0.8)	0.5	(0.3-0.7)	0.5	(0.3-0.8)
			0.4	(0.3-0.7)	0.3	(0.2-0.6)	0.4	(0.2-0.7)
					0.7	(0.4-1.5)	0.4	(0.2-0.9)
IBMTR-2	0.6^5-151	(0.4-0.9)	0.8^5-153	(0.5-1.4)	0.6	(0.4-1.1)	0.5	(0.3-0.9)
			0.3	(0.2-0.7)	0.6	(0.3-1.1)	1.0	(0.5-1.9)
					0.3	(0.1-1.4)	0.3	(0.1-1.0)
NMDP	0.6^5-151	(0.3-1.0)	0.5	(0.2-1.1)	N/A		0.4	(0.2-1.2)
			0.6	(0.3-1.1)			0.7	(0.3-1.5)
							1.0	(0.3-2.9)

Cohort	Any cGVHD		Lim, ext		Mild, mod, sev		Low, int, high
Cohort	RR^5-150	95% CI	RR^5-150	95% CI	RR^5-150	95% CI	RR^5-150	95% CI
IBMTR-1	0.5^5-152	(0.3-0.7)	0.5	(0.3-0.8)	0.5	(0.3-0.7)	0.5	(0.3-0.8)
			0.4	(0.3-0.7)	0.3	(0.2-0.6)	0.4	(0.2-0.7)
					0.7	(0.4-1.5)	0.4	(0.2-0.9)
IBMTR-2	0.6^5-151	(0.4-0.9)	0.8^5-153	(0.5-1.4)	0.6	(0.4-1.1)	0.5	(0.3-0.9)
			0.3	(0.2-0.7)	0.6	(0.3-1.1)	1.0	(0.5-1.9)
					0.3	(0.1-1.4)	0.3	(0.1-1.0)
NMDP	0.6^5-151	(0.3-1.0)	0.5	(0.2-1.1)	N/A		0.4	(0.2-1.2)
			0.6	(0.3-1.1)			0.7	(0.3-1.5)
							1.0	(0.3-2.9)

For abbreviations see Table 3.

F5-150

Adjusted for disease type (acute myelogenous leukemia, acute lymphoblastic leukemia, chronic myelogenous leukemia), disease stage (early, intermediate, advanced), age (years), patient-donor sex matching, and presence of prior acute GVHD (yes, no).

F5-151

P ≤ .01 compared with no cGVHD.

F5-152

P ≤ .0001 compared with no cGVHD.

F5-153

P ≤ .01 compared with the next most severe category.

View Large

This Feature Is Available To Subscribers Only